Senseonics (NYSE:SENS) shares rose today on first-quarter results that beat the consensus forecast.
The Germantown, Md.–based diabetes management technology developer posted losses of –$249.5 million, or –68¢ per share, on sales of $2.8 million for the three months ended March 31, 2021, registering a massive bottom-line slide from losses of –$42.6 million this time one year ago despite increasing sales from just $36,000 year-over-year.
Get the full story at our sister site, Drug Delivery Business News.